Remote, Postpartum BP Checks Feasible in Women With HTN
MONDAY, Sept. 16, 2019 -- A remote blood pressure monitoring program is feasible and acceptable to postpartum women with hypertension, according to a study published online Sept. 10 in Obstetrics & Gynecology.
Alisse Hauspurg, M.D., from University of Pittsburgh School of Medicine, and colleagues conducted a quality improvement project among 409 women admitted to the postpartum unit of a single tertiary care hospital with a diagnosis of chronic hypertension with superimposed preeclampsia (12 percent), gestational hypertension (41 percent), preeclampsia (44 percent), or postpartum preeclampsia (3 percent). The intervention (February 2018 to January 2019) included remote blood pressure monitoring and monitoring reminders and follow-up appointments. The frequency of the reminders and follow-up appointments was dependent on patients' readings, which were integrated into their electronic health records.
The researchers found that 171 participants (42 percent) had antihypertensives initiated or titrated through the program. The vast majority of women (83 percent) continued the program beyond three weeks postpartum, and 88 percent attended an in-person six-week postpartum visit. A postprogram survey was completed by 250 women, of whom 94 percent reported satisfaction with the program.
"We're meeting women where they are instead of saying they have to come to the hospital for all these blood pressure checks when they have a new baby," Hauspurg said in a statement. "I think this is supported by recent American College of Obstetricians and Gynecologists' recommendations and is an opportunity to improve care for high-risk women."
© 2020 HealthDay. All rights reserved.
Posted: September 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.